Literature DB >> 15569778

The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda.

Grant Dorsey1, Anne F Gasasira, Rhoderick Machekano, Moses R Kamya, Sarah G Staedke, Alan Hubbard.   

Abstract

Antimalarial drug treatment policy in sub-Saharan Africa is generally guided by the results of clinical drug efficacy studies in patients with uncomplicated Plasmodium falciparum malaria. The selection criteria used to enroll these patients often vary and may have a significant impact on treatment outcomes. In Kampala, Uganda, we investigated the impact of age, baseline temperature, and pre-treatment parasite density on estimates of treatment efficacy using a statistical modeling approach in 2,138 patients enrolled in six clinical trials involving seven different treatment regimens. Decreasing age, increasing temperature, and increasing parasite density were all independent predictors of an increased risk of treatment failure across all treatment groups. Compared with an unrestrictive approach to subject selection, enrolling only patients fulfilling selection criteria recommended by the World Health Organization (age < 5 years old, documented fever, and parasite density < 200,000/microL) increased the risk of treatment failure by 25-60% for the different treatment regimens. Caution should be taken when comparing results from drug efficacy studies with different subject selection criteria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15569778

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  23 in total

1.  Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children.

Authors:  Margaret Pinder; Colin J Sutherland; Fatoumatta Sisay-Joof; Jamila Ismaili; Matthew B B McCall; Rosalyn Ord; Rachel Hallett; Anthony A Holder; Paul Milligan
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Malaria in a holoendemic area of Burkina Faso: a cross-sectional study.

Authors:  August Stich; Nadja Oster; Inas Z Abdel-Aziz; Gabriele Stieglbauer; Boubacar Coulibaly; Hannes Wickert; Jeremy McLean; Bocar A Kouyaté; Heiko Becher; Michael Lanzer
Journal:  Parasitol Res       Date:  2006-01-14       Impact factor: 2.289

3.  Multiplicity of Plasmodium falciparum infection predicts antimalarial treatment outcome in Ugandan children.

Authors:  Daniel J Kyabayinze; Charles Karamagi; Moses Kiggundu; Moses R Kamya; Fred Wabwire-Mangen; Fred Kironde; Ambrose Talisuna
Journal:  Afr Health Sci       Date:  2008-12       Impact factor: 0.927

4.  Host candidate gene polymorphisms and associated clearance of P. falciparum amodiaquine and fansidar resistance mutants in children less than 5 years in Cameroon.

Authors:  Innocent Mbulli Ali; Marie-Solange Bebandue Evehe; Palmer Masumbe Netongo; Barbara Atogho-Tiedeu; Mbuh Akindeh-Nji; Honore Ngora; Irenee Kamogne Domkam; Mahamadou Diakite; Khan Baldip; Lisa Ranford-Cartwright; Patrice Nsangou Mimche; Tracey Lamb; Wilfred Fon Mbacham
Journal:  Pathog Glob Health       Date:  2014-11-12       Impact factor: 2.894

5.  Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.

Authors:  Piero Olliaro; Abdoulaye Djimdé; Grant Dorsey; Corine Karema; Andreas Mårtensson; Jean-Louis Ndiaye; Sodiomon B Sirima; Michel Vaillant; Julien Zwang
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

6.  Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children.

Authors:  Akintunde Sowunmi; Elsie O Adewoye; Grace O Gbotsho; Christian T Happi; Abayomi Sijuade; Onikepe A Folarin; Titilope M Okuboyejo; Obaro S Michael
Journal:  Malar J       Date:  2010-02-15       Impact factor: 2.979

7.  Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children.

Authors:  Steffen Borrmann; Pierre-Blaise Matsiegui; Michel Anoumou Missinou; Peter G Kremsner
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

8.  Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.

Authors:  Liusheng Huang; Sunil Parikh; Philip J Rosenthal; Patricia Lizak; Florence Marzan; Grant Dorsey; Diane Havlir; Francesca T Aweeka
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

9.  Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis.

Authors:  Julien Zwang; Piero Olliaro; Hubert Barennes; Maryline Bonnet; Philippe Brasseur; Hasifa Bukirwa; Sandra Cohuet; Umberto D'Alessandro; Abdulaye Djimdé; Corine Karema; Jean-Paul Guthmann; Sally Hamour; Jean-Louis Ndiaye; Andreas Mårtensson; Claude Rwagacondo; Issaka Sagara; Albert Same-Ekobo; Sodiomon B Sirima; Ingrid van den Broek; Adoke Yeka; Walter R J Taylor; Grant Dorsey; Milijaona Randrianarivelojosia
Journal:  Malar J       Date:  2009-08-23       Impact factor: 2.979

10.  Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.

Authors:  Nicholas J White; Wirichada Pongtavornpinyo; Richard J Maude; Sompob Saralamba; Ricardo Aguas; Kasia Stepniewska; Sue J Lee; Arjen M Dondorp; Lisa J White; Nicholas P J Day
Journal:  Malar J       Date:  2009-11-11       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.